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Brief Report
Route of Insulin Does Not Influence
25-Hydroxyvitamin D Concentrations
in Type 1 Diabetes: A
Brief Report
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The increased prevalence of vitamin D [25(OH)D] deficiency in type 1 diabetes mellitus (T1DM) may be
related to low insulin levels in the hepatic portal venous system. In this prospective matched-control
study, we demonstrate that long-term intraperitoneal insulin does not influence 25(OH)D concen-
trations in patients with T1DM as compared with subcutaneous insulin administration.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Type 1 diabetes mellitus (T1DM) is associated with an increased prevalence of vitamin D
deficiency [1]. As insulin influences the activity of (hepatic) 25-hydroxylase, the enzyme that
converts dietary vitamin D into calcidiol [25-hydroxyvitamin D, or 25(OH)D], a lower insulin
concentration in the hepatic portal vein may influence vitamin D metabolism [2–4]. With
continuous intraperitoneal insulin infusion (CIPII), insulin is infused in the intraperitoneal
space, where insulin is absorbed via the capillaries of the visceral peritoneum and to a large
extent into the portal vein [5–7]. We hypothesized that 25(OH)D concentrations are affected
by the route of insulin administration [CIPII or subcutaneous (SC)] and that CIPII results in
higher concentrations of 25(OH)D as compared with SC insulin administration.
1. Patients and Methods
This study is a post hoc analysis of a multicenter investigator-initiated study with a pro-
spective, observational matched case-control design. The full study design is described else-
where [8]. In short, patients with T1DM, aged 18 to 70 years, HbA1c $58 mmol/mol, and/or
five or more incidents of hypoglycemia (defined as glucose concentrations ,4.0 mmol/L) per
week were eligible. Cases were subjects on CIPII using an implanted insulin pump (MIP
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CIPII, continuous intraperitoneal insulin infusion; CSII, continuous subcutaneous
insulin infusion; MDI, multiple daily injection; SC, subcutaneous; T1DM, type 1 diabetes mellitus.
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2007D; Medtronic/MiniMed, Northridge, CA) for at least 4 years before inclusion in the study.
The SC control group, using multiple daily injections (MDIs) or continuous subcutaneous
insulin infusion (CSII), was age- and sex-matched to the cases. Measurements were made at
baseline and after 6 months. A 25(OH)D deficiency was defined as concentrations,50 nmol/L.
Using a general linear model, to adjust for possible baseline differences, the difference in
25(OH)D between the CIPII and SC groups over time was analyzed. Multivariate regression
analysis was performed with 25(OH)D averaged over the study period as dependent variable
and the average HbA1c, calcium, PTH, total insulin plasma concentrations, and insulin mode
(CIPII or SC) as covariates. Results are expressed asmean (with SD) ormedian (with interquartile
range) for normally distributed and nonnormally distributed data, respectively. The study protocol
was registeredprior to the start of the study (NCT01621308andNL41037.075.12) andapprovedby
the local medical ethics committee. All patients gave informed consent.
2. Results
Of the 183 patients eligible for analysis, 11 patients (3 CIPII, 7 MDI, and 1 CSII) were
excluded because of insufficient blood samples and 25 patients (7 CIPII, 9 MDI, and 9 CSII)
were excluded because of the use of vitamin D supplements. Subsequently, 147 patients (29
CIPII, 54 MDI, and 64 CSII) were analyzed. Of these patients, 41% were male with a mean
age 49 (12) years, diabetes duration 23 (17, 35) years, BMI 26 (4) kg/m2, HbA1c of 64 (11)
mmol/mol, and a total insulin dose of 0.6 (0.5, 0.8) units/kg/d. There were no differences in
baseline characteristics between the CIPII and SC group.
A 25(OH)D deficiency was present in 61 (42%) of the patients included in the analysis: 16 of
these patients were treated with CIPII and 45 with SC insulin (19 MDI and 26 CSII) (P 5
0.15). As presented in Table 1, concentrations of calcium, phosphate, magnesium, and PTH
changed significantly during the study period within the SC treatment group, whereas they
remained stable in the CIPII group. The estimated mean 25(OH)D concentration over the
study period was not significantly lower in the CIPII group as compared with the SC group:
58.3 (95% CI 51.1, 65.6) vs 64.6 (95% CI 60.8, 65.6) with amean difference of 6.3 (95% CI21.9
to 14.5) nmol/L. Except for higher alkaline phosphatase concentrations in the CIPII group,
there were no other significant differences between groups. In multivariable analysis with
25(OH)D as the dependent variable, only calcium was significant [b: 43.4; SE: 8.0 (95% CI
27.5, 59.2) with R2 5 0.19 for the model].
Comparisons between CIPII and the MDI and CSII groups and the comparisons between
included and excluded patients also revealed no differences between groups.
3. Discussion
No considerable differences between CIPII and SC insulin administration regarding 25(OH)D
concentrations and related parameters were observed in the current study. Moreover, in multi-
variate regression, no influence of both the route as the total daily dose of insulin on 25(OH)D
concentrationswas present. These findings are in contrast to those of Colette et al. [3], who observed
higher 25(OH)D, but identical 1,25(OH)2D, levels among 13 patients treated with CIPII as
comparedwith28persons treatedwithSC insulin. The25(OH)Dconcentrationsamong thepatients
treated with SC insulin in the study by Colette et al. [3] were lower as compared with our study
(;32 nmol/L vs 65 nmol/L), whereas concentrations among CIPII-treated patients were similar.
Although differences in study design may account for these discrepancies, we hypothesize that the
duration of insulin therapy ($4 years in the current study as compared with several months in the
study by Colette et al. [3]) may have induced adaption of 25-hydroxylase enzyme activity and
thereby normalization of 25(OH)D. Because decreased bone synthesis and strength are already
present early in the course T1DM, we cannot exclude that the lack of influence of long-term
treatment with CIPII on vitamin Dmetabolism as found in this study has no clinical consequences
on bone mineral density [9]. Previous experiments in rodents suggested that insulin influences
(bone- and liver-derived) alkaline phosphatase concentrations [10, 11]. As such, it could be
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hypothesized that the higher alkaline phosphatase concentrations among patients treated with
CIPII, as compared with patients treated with SC insulin, are a result of differences of insulin
concentrations in the portal vein and/or the peripheral circulation. Nevertheless, it should be
emphasized that our data are unable to explain this finding. Besides the lack of information on bone
mineral density, other limitations should be taken into accountwhen interpreting the results of this
study, including the nonrandomized design, small numbers, direct insulin measurements, and the
lack of information on other indices of vitaminDmetabolism, including 1,25(OH)2DandFGF-23. In
contrast, we included parameters of vitamin D metabolism that are routinely used in clinical
practice; furthermore, plasma insulin concentrations and all other measurements were made on
two separate occasions.
Taken together, these findings may indicate that after long-term treatment, the route of
insulin administration does not influence 25(OH)D concentrations in T1DM.
Acknowledgments
Financial Support: This work was supported by grants from the Isala Innovatie and Weten-
schapsfonds (grant INNO1717) and the Zwols Wetenschapsfonds Isala Klinieken. Both sources had no
role in the study design, data collection, analysis, interpretation, or writing of the report.
Additional Information
Correspondence: Peter R. van Dijk, MD, PhD, Department of Internal Medicine, University
Medical Center Groningen, University of Groningen, HPA AA41, Groningen 9700 RB, Netherlands.
E-mail: p.r.van.dijk@umcg.nl.
Disclosure Summary: The authors have nothing to disclose.
Data Availability: The data sets generated and/or analyzed during the current study are not
publicly available but are available from the corresponding author on reasonable request.
References and Notes
1. Shen L, Zhuang Q-S, Ji H-F. Assessment of vitamin D levels in type 1 and type 2 diabetes patients:
results from metaanalysis. Mol Nutr Food Res. 2016;60(5):1059–1067.
2. Wongsurawat N, Armbrecht HJ, Zenser TV, Davis BB, Thomas ML, Forte LR. 1,25-dihydroxyvitamin
D3 and 24,25-dihydroxyvitamin D3 production by isolated renal slices is modulated by diabetes and
insulin in the rat. Diabetes. 1983;32(4):302–306.
3. Colette C, Pares-Herbute N, Monnier L, Selam JL, Thomas N, Mirouze J. Effect of different insulin
administration modalities on vitamin D metabolism of insulin-dependent diabetic patients. Horm
Metab Res. 1989;21(1):37–41.
4. van Dijk PR, Logtenberg SJJ, Gans ROB, Bilo HJG, Kleefstra N. Intraperitoneal insulin infusion:
treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. Clin
Endocrinol (Oxf). 2014;81(4):488–497.
5. Radziuk J, Pye S, Seigler DE, Skyler JS, Offord R, Davies G. Splanchnic and systemic absorption of
intraperitoneal insulin using a new double-tracer method. Am J Physiol. 1994;266(5 Pt 1):E750–E759.
6. Giacca A, Caumo A, Galimberti G, Petrella G, Librenti MC, Scavini M, Pozza G, Micossi P. Peritoneal and
subcutaneous absorption of insulin in type I diabetic subjects. JClinEndocrinolMetab. 1993;77(3):738–742.
7. Selam JL, Bergman RN, Raccah D, Jean-Didier N, Lozano J, Charles MA. Determination of portal
insulin absorption from peritoneum via novel nonisotopic method. Diabetes. 1990;39(11):1361–1365.
8. vanDijk PR, Logtenberg SJJ, Hendriks SH, Groenier KH, Feenstra J, Pouwer F, Gans RO, KleefstraN,
Bilo HJ. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes
mellitus. Neth J Med. 2015;73(9):399–409.
9. Thrailkill KM, Lumpkin CK, Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone?
Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735–E745.
10. Rubinacci A, Boniforti F, Tessari L. [Effect of insulin on the activity of bone alkaline phosphatase in
culture]. Minerva Endocrinol. 1991;16(4):187–191.
11. Nolasco EL, Zanoni FL, Nunes FPB, Ferreira SS, Freitas LA, SilvaMC,Martins JO. Insulinmodulates
liver function in a type I diabetes rat model. Cell Physiol Biochem. 2015;36(4):1467–1479.








roningen user on 15 August 2019
